This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Sign In
Don’t have an account?
  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Bayer cross
BAYER FOR PROFESSIONALSYour Resource Portal
  • Ophthalmology
  • EYLEA® (aflibercept) 8 mg
  • EYLEA® (aflibercept) 2 mg
  • Oncology
  • Nubeqa® (darolutamide)
  • Xofigo®▼ (radium-223 dichloride)
  • Cardiology
  • Beyonttra®▼ (acoramidis)
  • Kerendia®▼ (finerenone)
  • Xarelto® (rivaroxaban)
  • Women's Health
  • Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
  • Jaydess®▼ (13.5mg levonorgestrel)
  • Kyleena® (19.5mg levonorgestrel)
  • Mirena® (52mg levonorgestrel)
  • Qlaira® (estradiol valerate/dienogest)
  • Service Optimisation & Formularies
  • Risk Minimisation Materials
  • Ophthalmology
  • Oncology
  • Cardiology
  • Women's Health
  • Ophthalmology Resources
  • Oncology Resources
  • Cardiology Resources
  • Women's Health Resources
  • Ophthalmology Events & On Demand Webinars
  • Oncology Events & On Demand Webinars
  • Cardiology Events & On Demand Webinars
  • Women's Health Events & On Demand Webinars
  • Ophthalmology Learning Zone
  • Oncology Learning Zone
  • Cardiology Learning Zone
  • Women's Health Learning Zone
  • Ophthalmology Podcasts
  • Oncology Podcasts
  • Cardiology Podcasts
  • Women's Health Podcasts
closesearch
Recent Searches
      You are now leaving BayerPro

      The contents and the policies on the website you are visiting is not controlled by the BayerPRO team.
      Do you wish to continue?

      PA_Background

      Prostate Cancer Podcast Series

      ASCO GU 2025
      NUBEQA® (darolutamide)
      NUBEQA Prescribing Information
      PP-NUB-GB-2229, March 2025
      Conversations at ESMO 2025
      Doublet and triplet therapy in mHSPC – Who is the right patient?
      NUBEQA Prescribing Information
      PP-NUB-GB-2751, November 2025
      Conversations at ESMO 2025
      Considering comorbidities in your mHSPC patients.
      NUBEQA Prescribing Information
      PP-NUB-GB-2752, November 2025
      ESMO 2025
      NUBEQA® (darolutamide)
      NUBEQA Prescribing Information
      PP-NUB-GB-2700, October 2025